Table 2.
Outcomes of treatment with Tielle dressings after 4 weeks and 12 weeks *
| Total | PU | VLU | DFD | Other wounds | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 4 weeks† | 12 weeks‡ | Baseline | 4 weeks† | 12 weeks‡ | Baseline | 4 weeks† | 12 weeks‡ | Baseline | 4 weeks† | 12 weeks‡ | Baseline | 4 weeks† | 12 weeks‡ | ||
| (n = 6993) | (n = 4628) | (n = 2355) | (n = 1793) | (n = 1181) | (n = 606) | (n = 4180) | (n = 2862) | (n = 1313) | (n = 662) | (n = 394) | (n = 268) | (n = 358) | (n = 190) | (n = 168) | ||
| Changes of wound radius (%) | −69·2 | −78·2 | −67·4 | −79·1 | −69·3 | −77·1 | −71·6 | −78·5 | −77·7 | −83.0 | ||||||
| Changes of wound area (%) | −78·2 | −85·1 | −77·9 | −87·5 | −78·8 | −83·8 | −71·8 | −84·8 | −85·2 | −86·2 | ||||||
| Signs of infection (%) | ||||||||||||||||
| Present | 49·2 | 5·5 | 3·4 | 49·1 | 6·3 | 2·5 | 47.2 | 5·1 | 3·7 | 57·6 | 5·6 | 4·1 | 57·8 | 6·8 | 3·6 | |
| Exudation (%) | ||||||||||||||||
| None | 4·6 | 18·6 | 14·5 | 5·0 | 21·3 | 12·9 | 4·1 | 18·2 | 15·2 | 6·0 | 17·5 | 18·7 | 6·7 | 10·0 | 8·3 | |
| Healed | N/A | 43·3 | 59·1 | N/A | 38·9 | 57·8 | N/A | 43·1 | 57·9 | N/A | 51·5 | 59·0 | N/A | 57·9 | 73·8 | |
| Little | 37·2 | 29·8 | 19·6 | 40·0 | 31·1 | 24·3 | 36·7 | 30·5 | 19·4 | 36·4 | 25·4 | 15·7 | 32·1 | 19·5 | 10·7 | |
| Medium | 44·0 | 5·5 | 3·8 | 40·8 | 5·8 | 3·0 | 45·8 | 5·5 | 4·3 | 43·8 | 4·1 | 3·0 | 40·5 | 6·3 | 4·2 | |
| Strong | 13·4 | 1·2 | 1·2 | 14·0 | 1·1 | 0·8 | 12·8 | 1·3 | 1·3 | 12·7 | 0·5 | 0·7 | 18·4 | 2·1 | 2·4 | |
| Wound odour (%) | ||||||||||||||||
| None | 22·1 | 37·1 | 14·5 | 16·2 | 37·0 | 28·4 | 23·9 | 38·4 | 29·8 | 21·8 | 32·0 | 27·6 | 31·0 | 29·5 | 18·5 | |
| Healed | N/A | 43·3 | 59·1 | N/A | 38·9 | 57·8 | N/A | 43·1 | 57·9 | N/A | 51·5 | 59·0 | N/A | 57·9 | 73·8 | |
| Little | 38·8 | 13·6 | 19·6 | 38·0 | 16·9 | 10·7 | 39·7 | 12·9 | 7·7 | 37·3 | 11·4 | 9·0 | 35·5 | 8·4 | 5·4 | |
| Medium | 26·2 | 2·7 | 3·8 | 28·4 | 3·8 | 0·8 | 25·4 | 2·4 | 2·2 | 28·5 | 2·5 | 0·7 | 21·2 | 1·1 | 1·8 | |
| Strong | 11·4 | 1·2 | 1·2 | 16·2 | 1·0 | 0·3 | 9·5 | 1·4 | 0·4 | 11·5 | 0·8 | 0·4 | 10·3 | 0·5 | 0·6 | |
| Portion of necrotic tissue (%) | ||||||||||||||||
| None | 18·6 | 36·7 | 25·2 | 15·6 | 36·7 | 24·3 | 19·9 | 38·3 | 27·0 | 15·9 | 29·4 | 24·3 | 24·6 | 27·4 | 16·1 | |
| Healed | N/A | 43·3 | 59·1 | NA | 38·9 | 57·8 | N/A | 43·1 | 57·9 | N/A | 51·5 | 59·0 | N/A | 57·9 | 73·8 | |
| Small | 47·8 | 16·3 | 12·7 | 46·1 | 19·5 | 15·2 | 49·8 | 15·6 | 12·3 | 43·7 | 14·7 | 11·9 | 41·6 | 10·5 | 8·3 | |
| Extensive | 28·2 | 1·7 | 1·3 | 32·3 | 2·9 | 1·5 | 25·6 | 1·3 | 1·1 | 32·8 | 1·3 | 1·5 | 29·1 | 2·1 | 1·8 | |
| Entire area | 4·8 | 0·4 | 0·3 | 5·5 | 0·5 | 0·3 | 4·2 | 0·4 | 0·3 | 7·3 | 0·8 | 0·4 | 3·9 | 0·0 | 0·0 | |
| Portion of fibrinous adhesion (%) | ||||||||||||||||
| None | 1·7 | 21·7 | 16·6 | 11·0 | 23·2 | 16·2 | 9·7 | 21·9 | 17·4 | 13·4 | 17·8 | 17·2 | 15·9 | 16·8 | 11·9 | |
| Healed | N/A | 43·3 | 59·1 | N/A | 38·9 | 57·8 | N/A | 43·1 | 57·9 | N/A | 51·5 | 59·0 | N/A | 57·9 | 73·8 | |
| Small | 54·0 | 27·9 | 18·6 | 54·6 | 29·7 | 20·8 | 53·9 | 28·5 | 18·6 | 54·2 | 24·1 | 18·7 | 51·4 | 15·8 | 10·7 | |
| Extensive | 3·7 | 4·5 | 3·4 | 31·1 | 5·2 | 3·3 | 31·5 | 4·3 | 3·6 | 26·9 | 3·0 | 2·2 | 26·0 | 5·8 | 3·6 | |
| Entire area | 3·4 | 0·6 | 0·6 | 2·3 | 0·6 | 0·8 | 3·6 | 0·6 | 0·5 | 4·2 | 1·0 | 0·4 | 4·5 | 0·0 | 0·0 | |
N/A, not applicable; DFD, diabetic foot disease; SD, standard deviation; VLU, venous leg ulcers; PU, pressure ulcers.
*
Pooled data from two 4‐week and one 12‐week Phase‐IV studies.
†
Two studies.
‡
One study.